APOLLOHOSPNSEApollo Hospitals Enterprise Limited· Healthcare ServicesHighPositive
Announced Tue, 10 Feb, 2026 · 17:50 IST

Apollo Hospitals Q3FY26: PAT up 35%, declares Rs 10 interim dividend

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemEmphasis Of MatterResults View source PDFExplain this filing

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.0%Reaction day
₹7216.00
prior close
₹7405.00
announcement price
After-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.2%+3.9% vs market
Hospital peers, median of 23sector+1.3%+2.7% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty 100 and 2.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.6
10m
+2.7
15m
+2.7
30m
+2.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.0+0.2+3.9+1.3+2.7
Next day
+4.5-0.4+4.9+2.3+2.2
2d
+4.3-1.7+6.0+0.8+3.5
3d
+5.1-0.9+6.0+1.1+4.0
4d
+5.0-0.7+5.7+2.0+3.0
5d
+5.9-0.3+6.2+2.5+3.4
1w
+5.2-1.3+6.4-0.3+5.5
15d
+8.0-4.3+12.3-2.0+10.0
1m
+6.7-7.4+14.2-2.6+9.3
2m
+4.1-7.4+11.4-1.9+6.0
3m
+12.0-6.7+18.6+9.0+3.0
UpDownMarket · Nifty 100Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Apollo Hospitals reported Q3FY26 consolidated revenue of Rs 6,477 crore, up 17% YoY. EBITDA grew 27% to Rs 965 crore. PAT rose 35% to Rs 502 crore. Diluted EPS stood at Rs 34.94. For 9M FY26, revenue grew 15% to Rs 18,623 crore and PAT rose 34% to Rs 1,412 crore. Board declared an interim dividend of Rs 10 per share, 200% on face value of Rs 5. Record date Feb 16, payment by Feb 27.

Likely market impact

Strong Q3 with broad growth across hospital, pharmacy and digital verticals. Interim dividend rewards shareholders. Demerger scheme filed with NCLT.